![]() ![]() ![]() The agency’s antitrust scrutiny has led five hospitals to abandon merger plans over the last two years. Under the Biden administration, healthcare has been a prime focus for the FTC, which examines deals and conduct involving hospitals and physician practices, pharmaceuticals and medical devices. In 2022, Tepezza brought in $1.97 billion in revenue and Krystexxa $716 million in revenue for Horizon, according to company filings. including Tepezza, used to treat thyroid eye disease, and Krystexxa, for chronic refractory gout - that do not face competition, the FTC said. Horizon distributes 11 drug products in the U.S. President Biden could have forced a price cut but didn’t.Īmgen has 27 approved drugs, including blockbuster treatments such as Enbrel for rheumatoid arthritis and Otezla for psoriasis. His actions tell a different storyĪ prostate cancer drug developed at UCLA with federal funds costs more than three times as much in the U.S. Business Column: Biden says he wants to bring down drug prices. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |